Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2014

View Archived Issues

Clinical phase I/II results of gene therapy for Becker muscular dystrophy

Phase II clinical results for a three-drug combination against HCV infection

GlaxoSmithKline plans phase II study of GSK-2269557 for acute exacerbation of COPD

New antagonists of S1P3 revert neurodegeneration and neuroinflammation

Nippon Kayaku launches infliximab biosimilar in Japan

Osteopontin RNA aptamer shows potential for the treatment of heart failure

LCZ-696 granted accelerated assessment by CHMP in Europe

Fullerene polyaminocaproic acid tested against HSV infection

Medicines for Malaria Venture collaborates with Cipla and Strides

UCB and Daiichi Sankyo partner to commercialize lacosamide in Japan

Aerocrine plans rights issue to fund commercialization of asthma diagnostic

Bukwang Pharmaceutical acquires Contera Pharma

Fingolimod fails to achieve endpoint in phase III trial in PPMS

Rinat Neuroscience discloses new anti-glucagon receptor antibodies

Incyte patents novel JAK-1 inhibitors

Roche patent reports new anti-HBV compounds

New mu opioid receptor antagonists designed at Dr August Wolff

Suzhou Vivotide Biotechnologies discloses novel VEGFR-1 inhibitors

Dynavax regains rights to DV-1179 under GSK collaboration

Mochida seeks approval in Japan for Lexapro in social anxiety disorder

Janssen files for manufacturing and distribution approval for ibrutinib in Japan

MSD and Kyorin sign Japanese comarketing agreement for desloratadine

EMA accepts for review Imbruvica submission for Waldenstrom's macroglobulinemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...